In just a short time, Paladin has emerged as one of Canada's leading specialty pharmaceutical companies. Since our inception in 1996, our revenues have grown at a compounded annual growth rate of 111% and our profitability has ranked us among Canada's most profitable publicly traded pharmaceutical companies. Our growth is fostered by the relentless execution of our strategy of acquiring and in-licensing innovative pharmaceuticals for the Canadian market.